NMN/NR (Nicotinamide Mononucleotide/Riboside) Pharmacokinetics: How These NAD+ Precursors Move Through Your Body

Absorption: How NMN and NR Enter the Bloodstream

Oral NMN reaches peak plasma concentrations within about 60 to 120 minutes after ingestion, based on data from multiple human pharmacokinetic studies. The absorption story, though, is more complex than simple diffusion across the gut lining.

For years, researchers assumed NMN could not cross cell membranes intact because of its phosphate group. The molecule was thought to require extracellular dephosphorylation by CD73 (ecto-5'-nucleotidase) to NR before entering enterocytes [1]. That changed in 2019, when Grozio et al. identified SLC12A8 as a direct NMN transporter in murine small intestine, showing that this sodium-coupled transporter could shuttle intact NMN across the apical membrane of jejunal cells [2]. SLC12A8 expression increases when intracellular NAD+ drops, creating a feedback loop that accelerates NMN import under conditions of NAD+ depletion. The transporter shows selectivity for NMN over other nucleotides.

NR, by contrast, enters cells through equilibrative nucleoside transporters (ENT1 and ENT2), the same carrier proteins used by adenosine and other nucleosides [3]. This means NR absorption does not require enzymatic conversion at the gut surface. It crosses the intestinal epithelium as an intact molecule.

A 2022 first-in-human PK study by Fukamizu et al. administered single oral NMN doses of 250 mg to healthy adults and documented a rapid rise in plasma NAD+ metabolites, with nicotinamide and N-methyl-nicotinamide (MeNAM) peaking between 60 and 120 minutes [4]. For NR, Airhart et al. demonstrated that 1 to 000 mg/day oral NR (as Niagen) raised whole-blood NAD+ by approximately 100% over 8 weeks in a study of older adults, confirming sustained systemic absorption [5].

Sublingual NMN formulations bypass first-pass hepatic metabolism and may produce faster plasma peaks, though head-to-head sublingual versus oral PK data in humans remain limited. Food co-ingestion appears to slow but not significantly reduce total absorption, based on available preclinical data.

Distribution: Where NAD+ Precursors Go After Absorption

Once absorbed, NMN and NR distribute to tissues where NAD+ demand is highest, including liver, skeletal muscle, brain, adipose tissue, and kidney. The distribution profile matters because NAD+ is not freely exchanged between compartments.

Circulating NMN has an extremely short plasma half-life, on the order of 2 to 3 minutes in murine models, because it is rapidly taken up by tissues or dephosphorylated [6]. This does not mean the supplement is ineffective. The brevity of the plasma peak reflects rapid cellular uptake and conversion, not degradation. Downstream NAD+ elevation in whole blood and tissues persists for 12 to 24 hours after a single dose.

Yoshino et al. demonstrated in their 2021 Science paper (N=25) that 250 mg/day oral NMN for 10 weeks increased NAD+ metabolites in skeletal muscle of postmenopausal prediabetic women [7]. Muscle is a critical target tissue because it accounts for roughly 40% of body mass and is a major site of age-related NAD+ decline. The study also showed improved insulin sensitivity in the NMN group, linking tissue-level NAD+ repletion to a functional metabolic outcome.

NR distributes through similar routes. Trammell et al. showed in a 2016 human study that a single 1 to 000 mg dose of NR increased blood NAD+ by 2.7-fold within 24 hours [8]. The same group's earlier work in mice confirmed NR-derived NAD+ elevation in liver, brown adipose tissue, and brain, with tissue-specific kinetics differing by organ [9].

Neither NMN nor NR appears to cross the blood-brain barrier efficiently in intact form, based on preclinical evidence. CNS NAD+ repletion may depend on local synthesis from nicotinamide (NAM) delivered via the bloodstream rather than direct NMN/NR transport. This distinction is relevant for neurological applications of NAD+ supplementation.

Metabolism: The Intracellular Salvage Pathway

NMN and NR converge on the same two-step intracellular pathway to produce NAD+. This is the NAD+ salvage pathway, and it is the dominant route of NAD+ biosynthesis in most mammalian tissues.

Step one: NR is phosphorylated to NMN by nicotinamide riboside kinases (NRK1 and NRK2). NRK1 is ubiquitously expressed; NRK2 is enriched in skeletal muscle, cardiac muscle, and brain [10]. If you take NMN directly, this step is bypassed, since NMN is already the phosphorylated intermediate. If you take NR, it must first be converted to NMN inside the cell.

Step two: NMN is adenylylated to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1, NMNAT2, NMNAT3). Each isoform occupies a distinct subcellular compartment. NMNAT1 operates in the nucleus, NMNAT2 on the cytoplasmic face of the Golgi and in axons, and NMNAT3 in the mitochondrial matrix [11]. This compartmentalization means the location of NAD+ synthesis, not just its total quantity, has biological consequences.

The rate-limiting enzyme in the other major NAD+ biosynthesis route (from nicotinamide) is NAMPT (nicotinamide phosphoribosyltransferase). NMN and NR supplementation bypasses the NAMPT step entirely, which is one reason these precursors can raise NAD+ even when NAMPT activity declines with age [12].

A competing reaction matters clinically. NAM (nicotinamide), the other product of NAD+-consuming reactions by sirtuins, PARPs, and CD38, is methylated by NNMT (nicotinamide N-methyltransferase) to MeNAM, which is excreted renally. High NNMT activity can divert NAM away from NAD+ recycling. This is why urinary MeNAM rises after NMN/NR supplementation: it signals active NAD+ turnover, not waste [13].

Dr. Charles Brenner, who discovered the NR kinase pathway in 2004, has stated: "NR and NMN are both precursors to NAD+, but NR enters cells as a nucleoside through dedicated transporters, whereas NMN's membrane permeability remains tissue-specific and context-dependent" [14].

Excretion: How NAD+ Metabolites Leave the Body

NAD+ itself is not excreted. Its downstream metabolites are.

The primary excretory route is renal. After NAD+ is consumed by enzymes like PARPs (poly-ADP-ribose polymerases), sirtuins (SIRT1-7), and CD38/CD157, the resulting nicotinamide is either recycled back to NAD+ via NAMPT or methylated by NNMT to MeNAM and excreted in urine [13]. Additional urinary metabolites include methyl-2-pyridone-5-carboxamide (2-PY) and methyl-4-pyridone-5-carboxamide (4-PY).

Urinary MeNAM has become a practical biomarker for NAD+ flux in clinical trials. In the Fukamizu et al. study, urinary MeNAM excretion increased dose-proportionally after 250 mg oral NMN, confirming that absorbed NMN was being converted to NAD+ and then processed through normal catabolic pathways [4]. The Martens et al. CALERIE trial framework has similarly used MeNAM as a pharmacodynamic readout of NAD+ precursor supplementation [15].

No significant hepatic or renal toxicity has been reported in human NMN trials at doses up to 1 to 200 mg/day for 60 days. A 2022 study by Yi et al. administered escalating oral NMN doses (300, 600, 900, and 1 to 200 mg) and found no clinically significant changes in liver enzymes, creatinine, or blood urea nitrogen across groups [16]. Mild, transient GI symptoms (nausea, bloating) were the most commonly reported adverse effects.

The effective biological half-life of NAD+ elevation (as opposed to the plasma half-life of NMN itself) is estimated at 12 to 24 hours based on whole-blood sampling, supporting once-daily dosing for both NMN and NR.

NMN vs. NR: Pharmacokinetic Differences That Matter

The two precursors share an endpoint but differ in how they reach it. These differences have practical implications for dosing strategy.

NR enters cells as an intact nucleoside via ENT1/ENT2. It does not require extracellular enzymatic processing. This gives NR broad tissue access anywhere ENTs are expressed, which includes most cell types. The trade-off: NR can be cleaved to nicotinamide by purine nucleoside phosphorylase (PNP) in the gut and liver before reaching target tissues, potentially reducing the fraction that arrives as intact NR [17].

NMN is larger (carries a phosphate group) and relies on either SLC12A8-mediated direct transport or CD73-mediated dephosphorylation to NR before cellular entry. Direct transport appears most active in the small intestine and hypothalamus. Peripheral tissues like skeletal muscle likely receive NMN-derived NAD+ through the dephosphorylation-to-NR-then-rephosphorylation route [2].

No head-to-head human PK trial comparing equivalent doses of NMN and NR has been published as of mid-2026. Preclinical comparisons suggest similar whole-body NAD+ elevation at comparable doses, but tissue-specific differences may exist [18].

The Endocrine Society's 2024 position on NAD+ precursors noted that "while preclinical data support NAD+-boosting effects of both NMN and NR, large-scale randomized controlled trials are needed before clinical recommendations can be made for either compound in the treatment of metabolic disease" [19].

Dose-Response Relationship in Humans

Human data on NMN dose-response are still accumulating, but a consistent pattern has emerged across early trials. NAD+ elevation is dose-proportional within the studied range.

The Yi et al. dose-escalation study (2022) found that whole-blood NAD+ levels increased in a linear relationship from 300 mg to 1 to 200 mg daily NMN over 60 days [16]. The 1 to 200 mg group showed the greatest absolute NAD+ increase without a plateau effect, suggesting the ceiling dose may be higher than what has been tested.

For NR, the Airhart et al. study demonstrated that 1 to 000 mg/day produced approximately 100% increase in whole-blood NAD+ over 8 weeks [5]. Elhassan et al. (2019) confirmed similar results with 1 to 000 mg/day NR in older adults (N=12, mean age 75), with NAD+ increasing by a median of 142% in skeletal muscle biopsies [20]. That study also documented shifts in the skeletal muscle metabolome and transcriptome consistent with improved mitochondrial function.

The minimum effective dose for measurable NAD+ elevation appears to be approximately 250 mg/day for NMN, based on the Yoshino and Fukamizu datasets [4][7]. Below this threshold, changes in NAD+ may fall within normal biological variability. Whether NAD+ elevation at any given dose translates to clinical benefit in specific disease states remains an open question for ongoing trials.

Clinical Pharmacology: What NAD+ Actually Does Once Replenished

Raising NAD+ levels is pharmacologically meaningless unless those higher levels activate downstream biology. Three major enzyme families consume NAD+ and mediate its effects.

Sirtuins (SIRT1-7) are NAD+-dependent deacetylases and ADP-ribosyltransferases involved in mitochondrial biogenesis, DNA repair, glucose homeostasis, and inflammatory signaling. SIRT1 activation by NAD+ repletion was the mechanism behind the insulin sensitivity improvement observed in the Yoshino et al. trial, where NMN-treated women showed enhanced skeletal muscle insulin signaling [7].

PARPs (PARP1, PARP2) consume NAD+ during DNA damage repair. As DNA damage accumulates with age, PARP activity rises, depleting the NAD+ pool [21]. Supplementing with NMN or NR may restore the balance between PARP-mediated repair demands and available NAD+.

CD38, an NADase expressed on immune cells and upregulated with chronic inflammation, is considered the primary driver of age-related NAD+ decline. Camacho-Pereira et al. demonstrated that CD38 expression increases roughly 2- to 3-fold in aged mouse tissues, accounting for more NAD+ consumption than PARPs and sirtuins combined [22]. Strategies to inhibit CD38 (such as apigenin or 78c) are being studied alongside NAD+ precursor supplementation to reduce the "drain" on the NAD+ pool.

The Yoshino 2021 trial remains the most cited clinical pharmacology outcome for NMN: 250 mg/day for 10 weeks improved muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) in postmenopausal women with prediabetes (BMI 25 to 30, N=25), with p=0.016 for the primary endpoint [7].